Impacts on clinical manifestations or on brain atrophy of the comorbid TDP-43 pathology in AD, PSP, and CBD patients have been reported [94,96,97], although whether the comorbid TDP-43 pathology is ‘bystander’ or ‘pathogenic’ is still controversial [106]. This evidence concerns the gene TARDBP and Brain atrophy.